We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase I Study of PEG-Paclitaxel In Patients With Advanced Solid Tumors & Lymphomas

This study has been terminated.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00023166
First Posted: August 27, 2001
Last Update Posted: December 9, 2005
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Enzon Pharmaceuticals, Inc.
  Purpose
Studies of PEG-paclitaxel have been terminated

Condition Intervention Phase
Neoplasm Lymphomas Neoplasm Metastasis Drug: PEG-paclitaxel Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I Study of PEG-Paclitaxel In Patients With Advanced Solid Tumors and Lymphomas

Resource links provided by NLM:


Further study details as provided by Enzon Pharmaceuticals, Inc.:

Study Start Date: May 2001
Estimated Study Completion Date: May 2002
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
None - Study has been terminated.
  Contacts and Locations
No Contacts or Locations Provided
  More Information

ClinicalTrials.gov Identifier: NCT00023166     History of Changes
Other Study ID Numbers: PTX-5001
First Submitted: August 24, 2001
First Posted: August 27, 2001
Last Update Posted: December 9, 2005
Last Verified: March 2004

Keywords provided by Enzon Pharmaceuticals, Inc.:
Phase I
Open label
Safety/efficacy
Lymphomas
Advanced primary and/or metastatic solid tumors
Neoplasms
Neoplasm metastasis

Additional relevant MeSH terms:
Lymphoma
Neoplasms
Neoplasm Metastasis
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Neoplastic Processes
Pathologic Processes
Paclitaxel
Albumin-Bound Paclitaxel
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action